Pharmacogenomics Testing Buoys Myriad Genetics Q3 Revenues While Coverage Remains an Open Question
Premium
Year-over-year pharmacogenomics testing revenues rose 34 percent, but $40 million could be at stake down the road if a decision by UnitedHealthcare goes into effect next year.
In the wake of suspending guidance to review the business in the first quarter of the year, QuidelOrtho has restructured and resumed offering a financial outlook.
A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.
The research team looked at cell-free DNA fragmentation profiles across the genome combined with measurements of two key biomarkers to detect ovarian cancer.
The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.
As the company explores new testing areas and technologies, the prostate cancer prognostic has become an important backbone.